Tuesday, October 31, 2017 6:25:48 PM
Not Drones
Mentioned it because one of the basic beliefs here is that CYDY has to get off the OTC to gain recognition. The referred outfit trades 20 to 30 times what you're seeing here lately.
I browsed an article that mentioned laudd and drones in the same para - probably in error. I used to have some AMBA so with curiosity I looked up Laudd - I didn't get to their profile because I bumped into their share volume.
Personally, I don't understand CYDY's share volume or price - maybe there's a need for better PR.
If someone buys CYDY at about 60 cents and the future holds bad news, the loss is about 60 cents. But, if the future holds good news, the gain is probably $2 to $5. If the probability of good vs bad news was roughly equal, the stock would seem to be a screaming buy. But, neither the price nor volume is saying that. In fact, the SP and volume were both higher a year ago.
Dunno!
M
Mentioned it because one of the basic beliefs here is that CYDY has to get off the OTC to gain recognition. The referred outfit trades 20 to 30 times what you're seeing here lately.
I browsed an article that mentioned laudd and drones in the same para - probably in error. I used to have some AMBA so with curiosity I looked up Laudd - I didn't get to their profile because I bumped into their share volume.
Personally, I don't understand CYDY's share volume or price - maybe there's a need for better PR.
If someone buys CYDY at about 60 cents and the future holds bad news, the loss is about 60 cents. But, if the future holds good news, the gain is probably $2 to $5. If the probability of good vs bad news was roughly equal, the stock would seem to be a screaming buy. But, neither the price nor volume is saying that. In fact, the SP and volume were both higher a year ago.
Dunno!
M
Recent CYDY News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/02/2025 10:15:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 01:40:20 PM
- CytoDyn Announces Resolution of Class Action Lawsuit • GlobeNewswire Inc. • 12/01/2025 01:30:00 PM
